Neue Publikation zur HIV-Therapie mit NVP

Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION)

Arasteh K, Ward D, Plettenberg A, Livrozet JM, Orkin C, Cordes C, Guo J, Wang E, Yong CL, Robinson P and
Quinson A

HIV Medicine (2012), 13, 236–244

zum Artikel